

Q-LINEA SIGNS FIRST SITE FOR US STUDY

Q-linea AB (publ) (OMX: QLINEA) today announced that the company has contracted Thermo Fisher Scientific as the first site to participate in the company's US clinical study for ASTar[®].

"This is very positive as it further strengthens our collaboration with Thermo Fisher Scientific. They have the reference method in susceptibility testing, which gives the study very good conditions, but it also opens up for further collaboration in the future," said Jonas Jarvius, CEO of Q-linea.

Just as in Europe, the interest in testing ASTar has been great at several hospitals and Q-linea will select at least one more American site for the US clinical study. The study is expected to begin during the second quarter of 2021. Thermo Fisher Scientific will be the reference site for all samples in the study.

ASTar is a fully automatic and user-friendly system for antibiotic susceptibility testing (AST) with a short hands-on time and the capability to deliver a broad answer within approximately six hours for positive blood cultures.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB Jonas.Jarvius@qlinea.com +46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB Anders.Lundin@qlinea.com +46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar[®] is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

Q-linea signs first site for US study